Advertisement
Canada markets open in 4 hours 3 minutes
  • S&P/TSX

    21,823.22
    +94.67 (+0.44%)
     
  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     
  • DOW

    38,225.66
    +322.37 (+0.85%)
     
  • CAD/USD

    0.7318
    +0.0004 (+0.06%)
     
  • CRUDE OIL

    79.00
    +0.05 (+0.06%)
     
  • Bitcoin CAD

    81,182.77
    +2,212.86 (+2.80%)
     
  • CMC Crypto 200

    1,283.60
    +6.62 (+0.52%)
     
  • GOLD FUTURES

    2,308.60
    -1.00 (-0.04%)
     
  • RUSSELL 2000

    2,016.11
    +35.88 (+1.81%)
     
  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     
  • NASDAQ futures

    17,755.00
    +105.25 (+0.60%)
     
  • VOLATILITY

    14.46
    -0.22 (-1.50%)
     
  • FTSE

    8,208.37
    +36.22 (+0.44%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6809
    -0.0008 (-0.12%)
     

1 Growth Stock Down 15.8% to Buy Right Now

Dad and son having fun outdoor. Healthy living concept
Image source: Getty Images

Written by Christopher Liew, CFA at The Motley Fool Canada

The healthcare market and wellness industry generally experienced a boom during the global pandemic. COVID-19 motivated nearly everyone to prioritize health, protect immune systems, and change lifestyles. Investors gravitated towards the healthcare sector and other stocks in various sectors with health-related businesses.

Jamieson Wellness (TSX:JWEL) rose to prominence at the height of the coronavirus breakout. Investors suddenly focused on the manufacturer, distributor, and seller of natural health products. In 2020, the consumer-defensive stock delivered a fat 42.4% capital gain.

Growth stock

A promising growth stock was born during the COVID period. Because of the heightened interest in health and wellness products, Jamieson’s revenue in 2020 increased 17% to $403.7 million versus 2019, while net income rose 31.4% year over year to $41.6 million.

ADVERTISEMENT

Its President and CEO then, Mark Hornick, said more than three years ago, “The COVID-19 pandemic has elevated health and wellness to become the top priority for consumers globally, and we are grateful for the role our brands play in supporting our consumers’ foundational health.”

Post-pandemic, investors’ interest in Jamieson waned, although it has remained profitable since 2020. Today, at $26.56 per share, the $1.1 billion company also pays a decent 2.66% dividend. Unfortunately, the stock trades at a discount (-15.8% year to date). Fortunately, the stalled growth could resume in 2024 and beyond.

Strong financial results

In Q4 2023, revenue and net earnings climbed 14.3% and 8.6% respectively to $220.4 million and $24 million versus Q4 2022. While the top line last year grew 23.5% year over year to $676.2 million, net earnings declined 12.8% to $46 million compared to 2022.

Still, current President and CEO Mike Pilato said, “2023 was a reflection of success on our strategic journey to become a global vitamin, mineral, and supplement leader. We drove growth across all our major markets and business units while successfully completing our 2022 U.S. acquisition integration and taking ownership of the full value chain in China.”

Pilato said further, “We are entering 2024 from a position of strength – strategically, operationally, and financially.” The diversification strategy and journey to expand the global footprint and increase market share beyond the home country are ongoing. Notably, international markets account for 40% of total branded revenue.

Jamieson will continue to prioritize investment in demand generation, innovation, and distribution in all our major markets to harness the full potential of the evolving needs of engaged consumers and significant industry growth tailwinds. Expect aggressive investments to grow its brands in the U.S. and China.

Business Outlook

For 2024, Jamieson Wellness projects consolidated revenue between $720 million and $760 million, or roughly 6.5% to 12.5% growth. The revenue growth guidance for Jamieson is from 12% to 18% or from $615 million to $650 million. Furthermore, business growth in the U.S. (13% to 20%) and China (60% to 80%) will outperform the Canadian market (4% to 7.5%).

After this year or in 2025, management anticipates a return to low double-digit growth, although Jamieson Brands will continue to drive growth and profitability. The company’s broad product scope and strong innovation capabilities enable it to respond to changing consumer trends, preferences, and spending.

The post 1 Growth Stock Down 15.8% to Buy Right Now appeared first on The Motley Fool Canada.

Should you invest $1,000 in Jamieson Wellness right now?

Before you buy stock in Jamieson Wellness, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Jamieson Wellness wasn’t one of them. The 10 stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $15,578.55!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 32 percentage points since 2013*.

See the 10 stocks * Returns as of 3/20/24

More reading

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

2024